optic disc neovascularisation

Similar documents
Preliminary report on effect of retinal panphotocoagulation on rubeosis iridis and

Photocoagulation of disciform macular lesions

Extensive argon laser photocoagulation in the

Comparative electroretinograms in argon laser

Panretinal photocoagulation in central retinal vein

Retinal pigment epithelial detachments in the elderly:

Treatment of diabetic maculopathy by

Proliferative diabetic retinopathy

New vessel formation in retinal branch vein occlusion

Peripheral retinal ablation in the treatment of

Diabetologia 9 by Springer-Verlag 1978

Clinically Significant Macular Edema (CSME)

Diabetic Retinopathy. Barry Emara MD FRCS(C) Giovanni Caboto Club October 3, 2012

chorioretinal atrophy

Long-Term Visual Outcome in Proliferative Diabetic Retinopathy Patients After Panretinal Photocoagulation

VISUAL OUTCOME IN DIABETIC MACULAR EDEMA AFTER GRID LASER TREATMENT

World Sight Day Case Studies. Mark Frost Screening Manager South East London DESP

Neovascular Glaucoma Associated with Cilioretinal Artery Occlusion Combined with Perfused Central Retinal Vein Occlusion

RETINAL DETACHMENT AT THE POSTERIOR POLE*

Ultrasonic examination in severe diabetic eye disease

Introduction How the eye works

Mild NPDR. Moderate NPDR. Severe NPDR

Prognosis for rubeosis iridis following central

FRANZCO, MD, MBBS. Royal Darwin Hospital

and non-diabetic subjects

RED KRYPTON AND BLUE-GREEN ARGON PANRETINAL LASER PHOTOCOAGULATION FOR PROLIFERATIVE DIABETIC RETINOPATHY: A LABORATORY AND CLINICAL COMPARISON*

Vitrectomy for Diabetic Cystoid Macular Edema

PART 1: GENERAL RETINAL ANATOMY


Diabetic Retinopathy

Mitsuko Yuzawa,* Takako Isomae,* Ryuzaburo Mori,* Hiroyuki Shimada* and Izumi Utsunomiya

Pit-like changes of the optic nerve head

NEPTUNE RED BANK BRICK

Original Article. Exudative Diabetic Maculopathy Treated By Frequancy Doubled Nd: Yag Laser (532nm)

Progression of diabetic retinopathy after cataract extraction

of diabetic retinopathy

The Human Eye. Cornea Iris. Pupil. Lens. Retina

Visual fields in diabetic retinopathy

The legally binding text is the original French version

Diabetic Retinopathy

Ophthalmology Macular Pathways

Retinitis pigmentosa and retinal oedema

Disease-Specific Fluorescein Angiography

Recurrent intraocular hemorrhage secondary to cataract wound neovascularization (Swan Syndrome)

MANAGING DIABETIC RETINOPATHY. <Your Hospital Name> <Your Logo>

Haemorrhagic glaucoma

Ophthalmology. Ophthalmology Services

Development and classification of rubeosis iridis

glaucoma and ocular hypertension

Fundus Autofluorescence. Jonathan A. Micieli, MD Valérie Biousse, MD

Amber Priority. Image Library

Diabetic Retinopathy WHAT IS DIABETIC RETINOPATHY? WHAT CAUSES DIABETIC RETINOPATHY? WHAT ARE THE STAGES OF DIABETIC RETINOPATHY?

Ocular findings in children with sickle

A Patient s Guide to Diabetic Retinopathy

Photocoagulation in proliferative sickle retinopathy:

Visual prognosis after panretinal photocoagulation for. Proliferative diabetic retinopathy (PDR)

GENERAL INFORMATION DIABETIC EYE DISEASE

Sorsby's pseudoinflammatory macular dystrophy

EFFICACY OF ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR AGENTS IN RETINAL DISORDER FOR BETTER VISUAL ACUITY

Reappraisal of the retinal cotton-wool spot: a discussion paper

Central venous occlusion

LASERS AND LATTE Richard G. Orlando, M.D., F.A.C.S.

Common Causes of Vision Loss

Test Bank for Medical Surgical Nursing An Integrated Approach 3rd Edition by White

Senile disciform macular degeneration

Michael P. Blair, MD Retina Consultants, Ltd Libertyville/Des Plaines, Illinois Clinical Associate University of Chicago 17 October 2015

S uperior segmental optic hypoplasia (SSOH), also termed

Year 2 MBChB Clinical Skills Session Ophthalmoscopy. Reviewed & ratified by: Mr M Batterbury Consultant Ophthalmologist

Retina Conference. Janelle Fassbender, MD, PhD University of Louisville Department of Ophthalmology and Visual Sciences 09/04/2014

Diabetes mellitus: A risk factor affecting visual outcome in branch retinal vein occlusion

PERIMETRIC LONG-TERM FOLLOW-UP OF DIABETIC CYSTOID MACULAR EDEMA AFTER LASER TREATMENT EXTENDED TO THE FOVEAL AVASCULAR ZONE

Retinal photocoagulation for proliferative sickle cell retinopathy: A prospective clinical trial with new sea fan classification

Diabetes and Eye Health more than meets the eye Vision Initiative - in association with PSA

Diabetic Eye Disease Visual Recognition & Interpretation of Clinical Signs

OCT Angiography in Primary Eye Care

EXUDATIVE DIABETIC RETINOPATHY* SPONTANEOUS CHANGES AND EFFECTS OF A CORN OIL DIET

Diabetic Retinopathy A Presentation for the Public

MAGNITUDE OF DIABETIC EYE DISEASE IN INDIA

Corneal blood staining after hyphaema

ROLE OF LASER PHOTOCOAGULATION VERSUS INTRAVITREAL TRIAMCINOLONE ACETONIDE IN ANGIOGRAPHIC MACULAR EDEMA IN DIABETES MELLITUS

Peripapillary circle of Zinn Haller revealed by fundus fluorescein angiography

ZEISS AngioPlex OCT Angiography. Clinical Case Reports

Angle-closure glaucoma secondary to

International Journal of Health Sciences and Research ISSN:

EyePACS Grading System (Part 3): Detecting Proliferative (Neovascular) Diabetic Retinopathy. George Bresnick MD MPA Jorge Cuadros OD PhD

Diabetic Retinopathy Clinical Research Network

THE CHRONIC GLAUCOMAS

Tuberous sclerosis presenting as atypical aggressive retinal astrocytoma with proliferative retinopathy and vitreous haemorrhage

Vanderbilt Eye Institute Clinical Trials

NEW YORK UNIVERSITY SCHOOL OF MEDICINE DEPARTMENT OF OPHTHALMOLOGY EDUCATIONAL OBJECTIVES AND GOALS

Pathogenesis and treatment of diabetic

Case Report: Indocyanine Green Dye Leakage from Retinal Artery in Branch Retinal Vein Occlusion

Widefield Retinal Imaging with Auto Fluorescence Technology in the Optometric Practice

laser photocoagulation in the treatment of central

Diagnosis and treatment of diabetic retinopathy. Blake Cooper MD Ophthalmologist Vitreoretinal Surgeon Retina Associates Kansas City

Indocyanine green angiography of the anterior segment in patients undergoing strabismus surgery

RETINAL CONDITIONS RETINAL CONDITIONS

Transpupillary thermotherapy (TTT) for the treatment of choroidal neovascularisation

Brampton Hurontario Street Brampton, ON L6Y 0P6

Transcription:

British Journal of Ophthalmology, 1979, 63, 412-417 A comparative study of argon laser and krypton laser in the treatment of diabetic optic disc neovascularisation W. E. SCHULENBURG, A. M. HAMILTON, AND R. K. BLACH From the Institute of Ophthalmology and Moorfields Eye Hospital, City Road, London SUMMARY A comparative study of the relative efficacy of the krypton and argon lasers in the treatment of disc new vessels in diabetic retinopathy was made. Resolution of the disc new vessels was achieved in both instances. There were clinical differences in the use and effects of the 2 lasers. Panretinal photocoagulation is an established method of treatment of proliferative diabetic retinopathy in eyes with optic disc neovascularisation (Cheng et al., 1976). However, marked shrinkage of visual fields often follows xenon-arc treatment because the burns frequently affect the nerve fibre layer of the retina (Hamilton et al., 1976). The ruby laser, although it does not give such field constriction, proves to be successful in only 21 % of eyes (Aiello et al., 1968). The argon laser photocoagulator was developed by L'Esperance (1968) so as to render precise control of the beam diameter, exposure time, and power. It is now widely used in the management of proliferative diabetic retinopathy and is particularly effective where neovascularisation involves the optic disc (Diabetic Retinopathy Study Research Group, 1976). The krypton laser photocoagulator differs from the argon laser photocoagulator in that it emits a red beam with a wavelength of 647-1 nm as opposed to a blue-green beam with the main wavelengths of 488-0 and 514-5 nm with the argon laser. Therefore, theoretically little energy from the krypton laser is absorbed by haemoglobin, which precludes direct coagulation of retinal blood vessels (Frangois and Cambie, 1977) (Fig. 1). The purpose of this study is to compare the effectiveness of argon laser photocoagulation with krypton laser photocoagulation in the treatment of diabetic optic disc neovascularisation by panretinal photocoagulation. Patients and methods Patients seen in the diabetic clinic with neovascularisation involving the optic disc, a vision of 6/9 or Address for reprints: Dr W. E. Schulenburg, Moorfields Eye Hospital, City Road, London EC1V 2PD Wavelength (nm) Fig. 1 Ocular transmission curve, absorption curve of melanin in the pigment epithelium (PE) and the choroid, and absorption curve of haemoglobin (Hgb) better, and who could attend for review were randomly selected for treatment by either the argon laser or the krypton laser. Patients were excluded from the study when treatment could not be completed in 1 treatment session. The Coherent 800 argon laser and the Lasertek krypton laser were used for treatment. The selection of treatment was in accordance with a preexisting randomised list. The new blood vessels on the optic disc were graded according to the Hammersmith classification of disc neovascularisation (Kohner et al., 1971). The method of treatment was by the technique of pan-photocoagulation, and this was completed in 1 session, a minimum of 2000 burns being applied (Hamilton et al., 1976). The 200-jtm spot size was used around the posterior pole and the 500-,um spot size further out in the periphery up to and beyond the equator. With both instruments the timing was set at 0-2 second and the intensity was adjusted until a 'light burn' was achieved. 412

Argon laser and krypton laser in the treatment of diabetic optic disc neovascularisation Table 1 Results Visual acuity Effect of treatment at 2 days 10/52 Number Annular Initial Grade at Pretreatment Post-treatment of burns Myopia Shallow AC choroidal grade of 10 weeks Complications detachment vessels Argon 1 6/9 6/9 2327 - - - 3 1 2 6/9 6/18 2012 - - - 2 2 Vitreous haemorrhage 3 6/9 6/9 2028 + + + 3 0 4 6/9 6/12 2052 - - 5 3 Vitreous haemorrhage 5 6/5 6/5 2024 - - - 2 0 6 6/5 6/5 2004 - - - 4 0 Krypton 1 6/9 6/9 2005 + + + 5 0 2 6/6 6/6 2000 + + + 2 0 3 6/9 6/9 2013 - - - 3 2 4 6/9 6/18 2037 + + + 5 3 Vitreous haemorrhage 5 6/9 6/9 2015 + + + 3 0 6 6/5 6/5 2003 - - - 5 0 Patients were evaluated initially, and at 1, 3, and 10 weeks. Corrected visual acuity and visual fields were tested, fluorescein angiography was carried out, and colour photographs were taken. In addition they were also examined on the second day after treatment for macular oedema, annular choroidal detachment, and anterior chamber depth. Results Twelve eyes in 8 patients qualified for the study. Six eyes were treated by the argon laser and 6 by the krypton laser. VISUAL ACUITY The majority of eyes retained their pretreatment visual acuities at 10 weeks after treatment. Vision deteriorated in only 3 eyes during the study owing to vitreous haemorrhages developing from persistent new vessels on the optic disc (Table 1). ANTERIOR CHAMBER DEPTH Examination on the second postoperative day showed shallow anterior chambers in 4 eyes treated by the krypton laser and in 1 eye treated by the argon laser, and all 5 eyes had an associated annular choroidal detachment. In none of the eyes with shallow anterior chamber and annular choroidal detachment was there any evidence of raised intraocular pressure. All 5 eyes showed a deterioration of their visual acuities and had myopia ranging from 3J.5 to -1-0 dioptres. Return to the previous refraction occurred 1 week after treatment. In no patients was macular oedema observed after treatment. VISUAL FIELDS Perimetry was done on the Goldmann perimeter with 3 different white targets. Objective V I I 4 4 2 Intensity The visual fields remained unchanged for V/4 throughout the study. There was an average centripetal shrinkage of 7 degrees for 1/4 in both groups 1 week after treatment and 10 degrees for 1/2. Ten weeks after treatment both groups showed some recovery of their visual fields, though it was more pronounced in the krypton-treated group with an Table 2 Average centripetalfield shrinkage 1 week and 10 weeks after treatment V/4 1/4 1/2 Argon 1 week 0 70 10 10 weeks 0 50 90 Krypton 1 week 0 70 10' 10 weeks 00 30 70 413

414 average centripetal shrinkage of 7 degrees for 1/2 and 3 degrees for 1/4 compared to 9 degrees and 5 degrees, respectively, in the argon laser-treated group (Table 2; Figs. 2 and 3). NEOVASCULARISATION ON OPTIC DISC Resolution of new vessels on the optic disc occurred in both groups in the study period (Figs. 4 and 5). In several eyes it was observed in both groups that the new vessels were not perfused when examined on the second day after treatment. This observation did not guarantee total regression of the disc vessels. W. E. Schulenburg, A. M.lHamilton, and R. K. Blach I Rol.t. Ime.s.... Diameter p.pill.. ) R G B Colo, 10X Correetio OD Visus, ph C - 2a Figs. 2a, b Pretreatment visual field and 10-week post-treatment field in an argon-treated eye 2b There was incomplete resolution of new vessels in 3 eyes belonging to the argon laser-treated group and 2 eyes in the krypton laser-treated group at the end of the study period (Table 1). Three of these eyes developed vitreous haemorrhages. SIDE EFFECTS Patients treated with the krypton laser more frequently complained of pain during treatment. In 3 patients in which 1 eye was treated with the krypton laser and the second eye with the argon laser a prominent subjective finding was that treatment

Argon laser and krypton laser in the treatment of diabetic optic disc neovascularisation 3a Figs. 3a, b Pretreatment visual field and 10-week post-treatment visual field in a krypton-treated eye 3b 415 Dl..we, ppillso Colo, C.'..tio Br J Ophthalmol: first published as 10.1136/bjo.63.6.412 on 1 June 1979. Downloaded from http://bjo.bmj.com/ with the krypton laser was more painful. This observation was also found in subsequent patients not recruited into this study. COMPLICATIONS On 3 occasions with the krypton laser heavy burns resulted in small haemorrhages, almost certainly derived from the choroidal circulation and developed from the outer border of the pigment halo surrounding the bum. The bleeding stopped within a few seconds and did not spread into the retrovitreal space. None of the patients receiving argon laser coagulation developed haemorrhages. With the krypton laser inadvertent coagulation of blood vessels produced no spasm of the vessel or haemorrhages. With the argon laser particular attention was applied to avoiding retinal blood vessels because of the known complication of spasm and haemorrhage from inadvertent coagulation (Hamilton et al., 1976). The average centripetal field shrinkage is smaller in the krypton laser-treated group after the 10-week period. Although the difference is small, its on 7 June 2018 by guest. Protected by copyright.

416 Fig. 4 after treatment in an argon-treated eye with complete regression of disc vessels W. E. Schulenburg, A. M. Hamilton, and R. K. Blach The appearance of the disc new vessels (a) before treatment; (b) within a few hours of treatment; (c) 1U weeks Fig. 5 (a) The appearance of the disc new vessels before treatment; (b) within a few hours of treatment; (c) 10 weeks after treatment in a krypton-treated eye with complete regression of the new vessels significance and subsequent evolution is not yet established. Discussion From this limited study the krypton laser appears to be as effective as the argon laser in causing regression of optic disc neovascularisation in diabetics, and throughout this study no difference was found in the response after photocoagulation. The krypton laser wavelength theoretically has a low absorption of energy by haemoglobin, and therefore coagulation of retinal capillaries and larger retinal blood vessels does not seem to be of importance (Marshall and Bird, in preparation). Thus the success of treatment appears to depend upon the effective absorption of energy by the pigment epithelium. Because of the absence of absorption by haemoglobin the krypton laser cannot be used for the direct coagulation of new vessels. In addition, if a haemorrhage occurs during treatment it is not possible to stop the flow of blood by coagulating the bleeding area. Of note is the high instance of annular choroidal detachment in the krypton-treated group, and this is of clinical importance because of the possibility of the precipitation of closed-angle glaucoma after treatment. The increased incidence of annular choroidal detachment in the krypton group may be a direct result of the more penetrating krypton burn affecting the larger choroidal vessels (Marshall and Bird, in preparation). A subjective significant finding was that treatment with the krypton laser was more painful, and it may be advisable to use a retrobulbar anaesthetic, especially when treatment is planned to be completed in 1 session. Once again this may be due to the greater penetration of the krypton burn. The krypton laser requires further evaluation to establish the effect on retinal blood vessels and also on the optic disc. In view of the lack of absorption

Argon laser and krypton laser in the treatment of diabetic optic disc neovascularisation by haemoglobin it may be of use in the treatment by panretinal photocoagulation of patients with mild to moderate vitreous haemorrhages. References Aiello, L., Beetham, W., Marios, C. B., Chazen, B. I., and Bradley, R. F. (1968). Ruby laser photocoagulation in treatment of diabetic proliferative retinopathy; preliminary report. In Symposium on Treatment of Diabetic Retinopathy, pp. 437463. Edited by M. Goldberg and S. Fine. US Department of Health, Education and Welfare publication no. 1890. Cheng, H. (1976). Response of proliferative diabetic retinopathy to xenon-arc phtocoagulation. A multicentre randomised controlled trial: second interim report. 417 Transactions of the Ophthalmological Societies of the United Kingdom, 96, 224-227. Diabetic Retinopathy Study Research Group (1976). Preliminary report on effects of photocoagulation therapy. American Journal of Ophthalmology, 81, 383-396. Franqois, J., and Cambie, E. (1971). Retinal photocoagulation (xenon-arc and lasers). Annals of Ophthalmology, 3, 1201-1208. Hamilton, A. M., Townshed, C.. Khoury, D., and Gould, E. (1976). Transactions of the Ophthalmological Societies of the United Kingdom, 96, 228-235. Kohner, E. M., Panisset, A., Cheng, H., and Fraser, T. R. (1971). Diabetes, 20, 816-823. L'Esperance, F. A., Jr. (1968). An ophthalmic argon laser photocoagulation system design, construction, and laboratory investigations. Transactions of the American Ophthalmological Society, 66, 827-904. Br J Ophthalmol: first published as 10.1136/bjo.63.6.412 on 1 June 1979. Downloaded from http://bjo.bmj.com/ on 7 June 2018 by guest. Protected by copyright.